Home › NDC Lookup › RxCUI directory › RxCUI 1433217

24 HR levomilnacipran 120 MG Extended Release Oral Capsule — RxCUI 1433217

RxNorm drug concept · Semantic clinical drug
RxCUI 1433217 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 10 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1433217
Official name24 HR levomilnacipran 120 MG Extended Release Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known aslevomilnacipran 120 MG (as levomilnacipran hydrochloride 137.8 MG) 24 HR Extended Release Oral Capsule; levomilnacipran 120 MG 24HR Extended Release Oral Capsule
FDA products mapped6
Package NDCs mapped10
Reported Medicaid activity (SDUD)17,968 prescriptions · 37 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Levomilnacipran: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Fetzima (levomilnacipran) is approved to treat major depressive disorder — MDD — in adults. It's in a class of antidepressants called SNRIs, which work by keeping certain mood-regu...
  • You take Fetzima once a day, and the good news is you can take it with or without food — whichever works better for you. The key rules are to swallow the capsule whole (don't open,...
  • How do I take this medication — does it matter if I eat first?
  • The most common side effects are nausea, constipation, sweating more than usual, and a faster heart rate — these often ease up as your body adjusts. Men may also notice changes in...
📖 Read our full Levomilnacipran guide →

🕸️ Concept Web — How 24 HR levomilnacipran 120 MG Extended Release Or... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR levomilnacipran 120 MG Extended Release Oral Capsule RxCUI 1433217

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Levomilnacipran 1433212
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Fetzima 1433218
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Levomilnacipran Extended Release Oral Capsule 1433216
    • Levomilnacipran Oral Product 1433214
    • Levomilnacipran Pill 1433215
    • Levomilnacipran Extended Release Oral Capsule [Fetzima] 1433220
    • Fetzima Oral Product 1433221
    • Fetzima Pill 1433222
    • Extended Release Oral Capsule 316943
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Levomilnacipran 120 MG SCDC · 1433213
  • Levomilnacipran Extended Release Oral Capsule SCDF · 1433216
  • Levomilnacipran Oral Product SCDG · 1433214
  • Levomilnacipran Pill SCDG · 1433215

Brand-Name Concepts

📦 FDA Products & Package NDCs

6 products · 10 package NDCs
10 package NDCs map to RxCUI 1433217 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00456-2200-07 1 BLISTER PACK in 1 CARTON (0456-2200-07) / 1 KIT in 1 BLIS... Fetzima Allergan, Inc. 2023-03-24
00456-2202-28 1 KIT in 1 BLISTER PACK (0456-2202-28) Fetzima Allergan, Inc. 2013-07-25
00456-2212-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0456-2212... Fetzima Allergan, Inc. 2013-07-25
00456-2212-90 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0456-2212... Fetzima Allergan, Inc. 2013-07-25
00456-2220-07 40 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0456-2220... Fetzima Allergan, Inc. 2013-07-25
00456-2220-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0456-2220... Fetzima Allergan, Inc. 2013-07-25
00456-2240-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0456-2240... Fetzima Allergan, Inc. 2013-07-25
00456-2240-90 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0456-2240... Fetzima Allergan, Inc. 2013-07-25
00456-2280-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0456-2280... Fetzima Allergan, Inc. 2013-07-25
00456-2280-90 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0456-2280... Fetzima Allergan, Inc. 2013-07-25
Observed labelers: Allergan, Inc. (10) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.